Korean AI company Rokit Healthcare enters Saudi Arabia with kidney disease prediction platform

Rokit Healthcare is bringing its AI-powered chronic kidney disease prediction platform to Saudi Arabia through a licensing deal with local healthcare company LifeHope. The agreement marks the Korean company's first major expansion into the Middle Eastern digital healthcare market.

The partnership goes beyond simple technology supply. Rokit Healthcare will receive 20% royalties on net sales while keeping its core technology protected. The company sees this as a template for global expansion of its AI prediction platform.

How will it work?

Rokit Healthcare will integrate its chronic kidney disease (CKD) prediction algorithm into LifeHope's "Longevity Platform." The AI can predict disease risk up to five years in advance.

The licensing structure protects Rokit's intellectual property:

• Algorithm supplied in object code only
• Source code, datasets and AI architecture remain with Rokit
• Non-exclusive license limited to Saudi Arabia
• 20% royalty on platform revenue

LifeHope will handle local market integration through its connections with hospital networks and insurance systems within Saudi Arabia's HEALTH SOCIETY framework. The company is backed by Albayat Medical, which owns the Albayat Medical Tower.

Why does it matter?

Saudi Arabia has a massive potential market for kidney disease screening. The country's high rates of diabetes and hypertension create perfect conditions for CKD prediction services.

The numbers are significant:

• CKD prevalence: 4.76% (1.2-1.7 million patients)
• Adult diabetes patients: 5.34 million
• Adults with hypertension: 5.1 million
• Total addressable market: 6-10 million people

Testing could cost around $100 per patient in the premium healthcare market. However, actual revenue will depend on hospital adoption rates, insurance coverage, regulatory approval and local partner performance.

The context

This deal represents a new business model for medical AI companies. Instead of selling software outright, Rokit Healthcare is creating recurring revenue streams through licensing agreements that can be replicated globally.

Saudi Arabia serves as Rokit's strategic entry point for the broader Middle East and North Africa region. The company plans to expand into other Gulf countries including the UAE, Qatar and Kuwait. The total GCC market could be several times larger than Saudi Arabia alone.

The timing aligns with Saudi Arabia's push for healthcare innovation and disease prevention. "Kidney disease is a serious issue in the Middle East, especially in Saudi Arabia, and the government is strongly supporting prevention and diagnostic initiatives," a LifeHope official said. "A technology capable of predicting disease risks five years in advance is something entirely new."